Compare VanEck Video Gaming and eSports ETF (ESPO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Video Gaming and eSports ETF vs Neurocrine Biosciences Inc — how do they compare? VanEck Video Gaming and eSports ETF trades at $91.98, while Neurocrine Biosciences Inc trades at $171.87 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals.
| ESPO | NBIX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $122.30 | $180.55 |
52-Week Low | $85.25 | $123.10 |
Market Cap | — | $17.30B |
Enterprise Value | — | $16.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESPO trades at $91.98, up 0.47% today, with technical indicators showing a bullish trend supported by moving averages. The ETF benefits from positive sentiment around AI-driven profit potential in the gaming industry. Recent institutional buying by Assetmark Inc. highlights growing confidence in the digital entertainment sector's growth prospects.
The outlook remains positive given AI's potential to boost gaming industry profits by $22 billion, though risks include sector competition and market volatility. Current technical strength near key support levels suggests potential for continued upward momentum if broader market conditions remain favorable.
Neurocrine Biosciences (NBIX) trades at $172.14, up 0.09% with strong bullish technical signals and consistent earnings beats. The company demonstrates robust fundamentals with 98.17% gross margins and 21.55% net income margin, supported by revenue growth from $2.86B to $3.1B projected. Recent news highlights pipeline advancements including Phase 2 studies and positive clinical data presentations at ENDO 2026.
NBIX presents compelling investment potential with 86% analyst buy ratings and $195.75 consensus target, offering 14% upside. Key catalysts include Q2 earnings on July 30 and continued pipeline execution. Risks involve clinical trial outcomes and competitive pressures in neuroscience therapeutics. The stock's valuation at 26.47 P/E appears reasonable given growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Video Gaming and eSports ETF
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
